Home » Stocks » LXRX

Lexicon Pharmaceuticals, Inc. (LXRX)

Stock Price: $6.87 USD -1.18 (-14.66%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.88 +0.01 (0.15%) Jan 15, 7:59 PM
Market Cap 972.08M
Revenue (ttm) 32.52M
Net Income (ttm) -104.22M
Shares Out 107.31M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.87
Previous Close $8.05
Change ($) -1.18
Change (%) -14.66%
Day's Open 7.48
Day's Range 6.55 - 7.76
Day's Volume 17,039,509
52-Week Range 1.05 - 8.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 day ago

Find out what led to the biotech industry's biggest gains.

Other stocks mentioned: ALDX, NCNA
The Motley Fool - 3 days ago

A downgrade from an analyst might have something to do with it.

Zacks Investment Research - 3 days ago

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

The Motley Fool - 4 days ago

The FDA delivered a powerful shot of good news to the company.

Benzinga - 4 days ago

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clin...

InvestorPlace - 4 days ago

Lexicon Pharmaceuticals (LXRX) stock is on the rise Thursday after announcing an update from the FDA for its drug sotagliflozin. The post LXRX Stock Alert: Why Lexicon Pharmaceuticals Is Up 10...

24/7 Wall Street - 4 days ago

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares jumped on Thursday morning after the company announced that it received regulatory feedback from the U.S.

GlobeNewsWire - 4 days ago

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory fee...

Zacks Investment Research - 2 weeks ago

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

GlobeNewsWire - 2 weeks ago

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, ...

Zacks Investment Research - 2 weeks ago

Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

InvestorPlace - 2 weeks ago

Lexicon Pharma sold LXRX stock to Weight Watchers' turn-around billionaire. Lexicon sold 15% of LXRX stock to Ray Debbane's private equity company which turned Weight Watchers around.

Other stocks mentioned: WW
Benzinga - 4 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ALXO, ATH, BH, GDYN, SNEX, SONA, UEPS, UHAL, VTRS
GlobeNewsWire - 1 month ago

THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD ...

The Motley Fool - 1 month ago

More clarification seems warranted for the company's shareholder-diluting move.

GlobeNewsWire - 1 month ago

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain insti...

GlobeNewsWire - 1 month ago

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Ad...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Benzinga - 1 month ago

Lexicon Pharmaceuticals (NASDAQ: LXRX) is currently up 93.64% to a price of $3.3. Tuesday the stock has been traded at a volume of 163.00 million, about 3138.31% of its recent 30-day volume av...

InvestorPlace - 1 month ago

Lexicon Pharmaceuticals (LXRX) stock is soaring higher on Tuesday after getting an upgrade from Citi analyst Yigal Nochomovitz. The post LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tues...

InvestorPlace - 2 months ago

Lexicon Pharmaceuticals (LXRX) news for Tuesday includes LXRX stock soaring higher on results from a Phase 3 clinical trial. The post Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43...

GlobeNewsWire - 2 months ago

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies Sotagliflozin Significantly Reduced...

GlobeNewsWire - 2 months ago

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference:

Seeking Alpha - 2 months ago

Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.

GlobeNewsWire - 2 months ago

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

GlobeNewsWire - 3 months ago

Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020

GlobeNewsWire - 4 months ago

Lexicon Receives $160.4 Million at Closing

GlobeNewsWire - 4 months ago

THE WOODLANDS, Texas, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-...

GlobeNewsWire - 4 months ago

THE WOODLANDS, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:

24/7 Wall Street - 5 months ago

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, IMGN, VKTX, XNCR
Seeking Alpha - 5 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Lexicon (LXRX) delivered earnings and revenue surprises of -12.28% and 5.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

GlobeNewsWire - 5 months ago

Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Lexicon to Receive Up to $224 Million in Upfron...

Benzinga - 5 months ago

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, CHRS, GEN, SLRX
Zacks Investment Research - 5 months ago

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 5 months ago

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.

GlobeNewsWire - 5 months ago

THE WOODLANDS, Texas, July 21, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabete...

GlobeNewsWire - 5 months ago

THE WOODLANDS, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting XERMELO ® (telotristat ethyl) will be ...

GlobeNewsWire - 7 months ago

THE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) --   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM (sotagliflozin) at the virtual 80th Ameri...

GlobeNewsWire - 7 months ago

THE WOODLANDS, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)  today announced that Lonnel Coats, President and Chief Executive Officer, will present ...

GlobeNewsWire - 8 months ago

THE WOODLANDS, Texas, May 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s ® (telotristat ethyl) antiproliferative e...

The Motley Fool - 8 months ago

The biotech company reported better-than-expected first-quarter results and now sees lower costs in 2020.

Seeking Alpha - 8 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Lexicon (LXRX) delivered earnings and revenue surprises of 4.55% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 9 months ago

THE WOODLANDS, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the ...

GlobeNewsWire - 9 months ago

Long-Term Outcomes Studies, SCORED and SOLOIST, to Close Out Early Long-Term Outcomes Studies, SCORED and SOLOIST, to Close Out Early

About LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabete... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2000
CEO
Lonnel Coats
Employees
184
Stock Exchange
NASDAQ
Ticker Symbol
LXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is 6.00, which is a decrease of -12.66% from the latest price.

Price Target
$6.00
(-12.66% downside)
Analyst Consensus: Buy